Loved this. Makes me wonder if the next frontier isn’t just GLP-1 expansion, but a broader appetite to tackle adjacent high-cost conditions like SUD. MAT has saved lives, but the system still fails too many — feels like we’re overdue for a step change in addiction care.
Thanks, David. IMO the downstream effects of GLP-1s on addiction is the most exciting area of research taking place right now. Scoring high on impulsiveness is associated with several behavioural conditions all of which are damaging to society. We need to have honest conversations (like, yesterday) on how the hell we make this drug accessible to everyone who may need it (once trial data proves efficacy for SUD).
Insurers will continue blocking GLP-1s as long as it’s profitable to do so. Truth is they are overpriced at current levels and a rate more in line with the rest of the world is needed. Ozempic gets negotiated by Medicare in August so we’ll see.
One thing to keep in mind is that if fat fucks take glp-1s and you have generous coverage then your going to get selected against by fat fucks buying your plan. Maybe they are slightly less fat on glp1s but they are still likely bad risks (claims higher than premiums). Some classes of insurance might be able to solve this with risk scores but government risk models tend to be wildly inaccurate and years behind the reality in the ground. Either you’re making a killing or getting killed by the mispricing.
i’m rather attached to my bad habits
Loved this. Makes me wonder if the next frontier isn’t just GLP-1 expansion, but a broader appetite to tackle adjacent high-cost conditions like SUD. MAT has saved lives, but the system still fails too many — feels like we’re overdue for a step change in addiction care.
Thanks, David. IMO the downstream effects of GLP-1s on addiction is the most exciting area of research taking place right now. Scoring high on impulsiveness is associated with several behavioural conditions all of which are damaging to society. We need to have honest conversations (like, yesterday) on how the hell we make this drug accessible to everyone who may need it (once trial data proves efficacy for SUD).
Insurers will continue blocking GLP-1s as long as it’s profitable to do so. Truth is they are overpriced at current levels and a rate more in line with the rest of the world is needed. Ozempic gets negotiated by Medicare in August so we’ll see.
One thing to keep in mind is that if fat fucks take glp-1s and you have generous coverage then your going to get selected against by fat fucks buying your plan. Maybe they are slightly less fat on glp1s but they are still likely bad risks (claims higher than premiums). Some classes of insurance might be able to solve this with risk scores but government risk models tend to be wildly inaccurate and years behind the reality in the ground. Either you’re making a killing or getting killed by the mispricing.
Perfect
Seems to me we’re just switching the billion dollar industry of high fat carbs to big pharmaceutical GLP-1’s.
Win/win for pharma, lose/lose for us.
Are you aware if there have been any similar brain scan studies on retatrutide as the tirzeptitide cited? Fascinating!